---
title: "GH Fragment 176-191"
canonical_url: https://peptidelibrary.app/library/gh-frag-176-191
description: "C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments)."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# GH Fragment 176-191

GH Fragment 176-191 (also called hGH 176-191 or AOD9604-related fragment) is a GH C-terminal fragment. This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism.

C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).

Also known as: hGH 176-191, AOD9604-related fragment, HGH Frag.

Categories: Fat Loss, Muscle/Recovery, GLP-1/Metabolic, Experimental.

## Classification

- Type: GH C-terminal fragment / research
- Mechanism class: Lipolytic GH fragment
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable. In rodent adipocyte studies the fragment increased lipolysis and reduced lipogenesis without raising IGF-1. Human evidence for meaningful fat loss is weak, and the fragment does not reproduce the anabolic effects of intact growth hormone.

Targets: Adipose lipolytic pathways.

Origin: Synthetic fragment of human growth hormone.

## Properties

- Molecular formula: C78H123N23O23S2
- Molecular weight: ≈1729 g/mol
- CAS number: 66004-57-7
- Half-life: Short (minutes–hours; animal PK)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. 2001. Preclinical: animal or lab study. Population: Obese mice and beta-3 adrenergic receptor knock-out mice. Lower body weight and body fat in obese mice; no weight effect in the knock-out mice. Research on a related compound, not this one. Limitations: Studied an analog, not GH Fragment 176-191 itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/11713213/)
2. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000. 2000. Preclinical: animal or lab study. Population: Obese (ob/ob) mice; isolated rodent and human fat tissue. Less weight gain from day 16, with no change in food intake. Research on a related compound, not this one. Limitations: Studied an analog, not GH Fragment 176-191 itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/10950816/)

## Safety

Side effects: Injection reactions; Uncertain efficacy.

Risks: WADA S2 prohibited.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

GH Fragment 176-191 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is GH Fragment 176-191?

C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).

### How does GH Fragment 176-191 work?

This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable.

### Is GH Fragment 176-191 FDA approved?

No. GH Fragment 176-191 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of GH Fragment 176-191?

Reported half-life for GH Fragment 176-191 is Short (minutes–hours; animal PK). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is GH Fragment 176-191 banned in sport?

GH Fragment 176-191 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to GH Fragment 176-191?

Compounds most often compared with GH Fragment 176-191 include AOD-9604, Human Growth Hormone (Somatropin), 5-Amino-1MQ and Adipotide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026](https://pubmed.ncbi.nlm.nih.gov/42395176/)
- [Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — Analyst, 2026](https://pubmed.ncbi.nlm.nih.gov/42328738/)
